These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://diegoduwb882869.blog5star.com/39534294/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide